Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$2.9M
Filings
78
Firms Hired
3
Active Period
2010–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
2026 · second_quarter · Firm: FOUNDATION MEDICINE, INC.
- Medicare coverage and reimbursement of clinical diagnostic laboratory tests, including changes to National Coverage Determination 90.2 issued by the Centers for Medicare and Medicaid Services - Modifications to the regulatory framework for clinical diagnostic laboratory tests, including companion diagnostics - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for Fiscal Year 2027 (H.R.8646, S.)
Client expense: $80,000 · Firm income: —
Matched citations: H.R.8646
Cancer Patient Equity Act of 2021
2025 · second_quarter · Firm: FOUNDATION MEDICINE, INC.
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory
Client expense: $80,000 · Firm income: —
Matched citations: H.R.5377
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory
Client expense: $80,000 · Firm income: —
Matched citations: H.R.2369
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory
Client expense: $80,000 · Firm income: —
Matched citations: H.R.3561
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
Client expense: $80,000 · Firm income: —
Matched citations: H.R.2369
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
Client expense: $90,000 · Firm income: —
Matched citations: H.R.2369
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
Client expense: $130,000 · Firm income: —
Matched citations: H.R.2369
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
Client expense: $110,000 · Firm income: —
Matched citations: H.R.2369
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Cancer Moonshot
Client expense: $90,000 · Firm income: —
Matched citations: H.R.2369
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Cancer Moonshot
Client expense: $90,000 · Firm income: —
Matched citations: H.R.3561
Cancer Patient Equity Act of 2021
2023 · third_quarter · Firm: FOUNDATION MEDICINE, INC.
Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377)
Client expense: $90,000 · Firm income: —
Matched citations: H.R.5377
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Cancer Moonshot
Client expense: $90,000 · Firm income: —
Matched citations: H.R.2369
- Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Cancer Moonshot
Client expense: $80,000 · Firm income: —
Matched citations: H.R.2369
- Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Cancer Moonshot
Client expense: $80,000 · Firm income: —
Matched citations: H.R.3561
- Issues Related to Data Privacy and Security - Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209,H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328) - Cancer Moonshot
Client expense: $100,000 · Firm income: —
Matched citations: H.R.4128
- Issues Related to Data Privacy and Security - Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209,H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328) - Cancer Moonshot
Client expense: $100,000 · Firm income: —
Matched citations: S.2209
- Issues Related to Data Privacy and Security - Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209,H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328) - Cancer Moonshot
Client expense: $100,000 · Firm income: —
Matched citations: S.4348
- Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328)
Client expense: $80,000 · Firm income: —
Matched citations: H.R.4128
- Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328)
Client expense: $80,000 · Firm income: —
Matched citations: S.2209
- Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328)
Client expense: $80,000 · Firm income: —
Matched citations: S.4348
- Issues related to data privacy and security - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and theVerifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and LandmarkAdvancements Act of 2022 (S.4348) - Cancer Moonshot
Client expense: $80,000 · Firm income: —
Matched citations: H.R.4128
Cancer Patient Equity Act of 2021
2022 · third_quarter · Firm: FOUNDATION MEDICINE, INC.
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377)
Client expense: $80,000 · Firm income: —
Matched citations: H.R.5377
- Issues related to data privacy and security - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and theVerifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and LandmarkAdvancements Act of 2022 (S.4348) - Cancer Moonshot
Client expense: $80,000 · Firm income: —
Matched citations: S.2209
- Issues related to data privacy and security - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and theVerifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and LandmarkAdvancements Act of 2022 (S.4348) - Cancer Moonshot
Client expense: $80,000 · Firm income: —
Matched citations: S.4348
Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) Issues related to health data privacy and security, including the American Data Privacy and Protection Act (H.R.8152) Issues related to the federal governments COVID-19 response, including liability reforms and supply chain issues
Client expense: $100,000 · Firm income: —
Matched citations: H.R.4128
Source: Senate LDA